Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of clinical trials is to evaluate safety and tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells as a treatment for Patients with Parkinson's disease.
This study is phase I/II clinical trials which is accessible to those involved in the study and conducted by only Bundang CHA hospital.
The progress of the clinical trails is reported to and evaluated by Data monitoring committee before the enrolment of next human subject.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Mesencephalic Neuronal Precursor Cells | Other |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Mesencephalic Neuronal Precursor Cells | Drug | All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients. |
| Measure | Description | Time Frame |
|---|---|---|
| Presence or absence of cancer foramtion and infection | If not included in the following criteria, the cells are are considered to be safe and tolerable.
| 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Score of Unified Parkinson's Disease Rating Scale (UPDRS) | UPDRS, most commonly used, is designed to assess the severity of parkinson's disease, making the quantitative measurement of the extent. Part III of UPDRS corresponds to motor evaluation and is the most reliable for detecting symptomatic progression. UPDRS improvement ratio(%) = ((the value of UPDRS before surgery - the value of UPDRS after surgery) / (the value of UPDRS before surgery)) X 100 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Sang Sup Chung, M.D., Ph.D. | Contact | 82-31-780-5261 | jmoon@cha.ac.kr | |
| Joo pyung Kim, M.D., Ph.D. | Contact | 82-31-780-5000 | jpkim@cha.ac.kr |
| Name | Affiliation | Role |
|---|---|---|
| Sang Sup Chung, M.D., Ph.D. | CHA University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHA Bundang Medical Center, CHA University | Recruiting | Seongnam-si | Gyeonggi-do | 463-712 | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 5 years |
| Detection of positron emission in Putamen using Positron emission tomograph(PET) | In pet analysis, putamen activity is investigated via radioactivity before cell transplantation and 12,24,36,48,60 months after the treatment. | 5 years |
| Dyskinesia scale scores(CAPSIT-PD) | Overall inspection was carried out before transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54, 60 months after the treatment for determining whether the cells have therapeutic effects. | 5 years |
| Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test | Comprehensive clinical assessment for examining the improvements in self reporting and timed testing before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment:Pronation-supination test, Hand/Arm movement between two points, finger dexterity, stand-walk-sit-test. | 5 years |
| Score of activity of daily living (ADL) scale | Comprehensive clinical assessment for examining the improvements in activity of daily living before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Score of Korean mini-mental examination (K-MMSE) | Comprehensive clinical assessment for examining the improvements in mental state before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Motor fluctuation scale scores | Comprehensive clinical assessment for identifying the presence of motor fluctuation symptoms before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Satisfaction score with patient questionnaire | Measure of patient satisfaction before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Dopaminergic drug dose | Measure of dopaminergic drug dose before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Tremor, postural instability, motor dysfunction, gait disturbance | Using video recording, assessment for symptoms such as tremor, postural instability, motor dysfunction and gait disturbance before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| Assessing the extent of recovery with patient's diary | Assessing the extent of recovery based on patient's diary before the cell transplantation and 1, 3, 6, 9, 12, 15, 18, 21, 24,30, 36, 42, 48, 54, 60 months after the treatment. | 5 years |
| ID | Term |
|---|---|
| D010300 | Parkinson Disease |
| ID | Term |
|---|---|
| D020734 | Parkinsonian Disorders |
| D001480 | Basal Ganglia Diseases |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D009069 | Movement Disorders |
| D000080874 | Synucleinopathies |
| D019636 | Neurodegenerative Diseases |
Not provided
Not provided